Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

Ryan Choi, Matthew A. Hulverson, Wenlin Huang, Rama S.R. Vidadala, Grant R. Whitman, Lynn K. Barrett, Deborah A. Schaefer, Dana P. Betzer, Michael W. Riggs, J. Stone Doggett, Andrew Hemphill, Luis Miguel Ortega-Mora, Molly C. McCloskey, Samuel L.M. Arnold, Robert C. Hackman, Kennan C. Marsh, James J. Lynch, Gail M. Freiberg, Bruce E. Leroy, Dale J. KempfRobert K.M. Choy, Eugenio L. de Hostos, Dustin J. Maly, Erkang Fan, Kayode K. Ojo, Wesley C. Van Voorhis

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Bumped Kinase Inhibitors, targeting Calcium-dependent Protein Kinase 1 in apicomplexan parasites with a glycine gatekeeper, are promising new therapeutics for apicomplexan diseases. Here we will review advances, as well as challenges and lessons learned regarding efficacy, safety, and pharmacology that have shaped our selection of pre-clinical candidates.

Original languageEnglish (US)
Pages (from-to)413-422
Number of pages10
JournalInternational Journal for Parasitology
Issue number5
StatePublished - May 2020


  • Apicomplexa
  • Bumped Kinase Inhibitor
  • Calcium-dependent Protein Kinases
  • Cryptosporidium
  • Gatekeeper
  • Neospora
  • Sarcocystis
  • Toxoplasma

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases


Dive into the research topics of 'Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned'. Together they form a unique fingerprint.

Cite this